Michael Lane, Executive Vice President at IDEXX Laboratories Inc /DE (NASDAQ:IDXX), filed a Form 4 on November 20, 2026, reporting the exercise of three incentive stock options on November 18, 2026, covering a total of 863 shares of common stock.

Key Highlights

  • Three option exercises: Lane exercised incentive stock options for 483 shares at $206.94, 183 shares at $544.08, and 197 shares at $505.53, all on November 18, 2026.
  • Direct ownership after transactions: Following the three exercises, Lane directly beneficially owned 4,939 shares of IDEXX common stock.
  • Indirect holdings: Lane's spouse holds 592 shares in an IRA account; the filing states Lane disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
  • Options fully exhausted: All three incentive stock option grants reported in Table II show zero derivative securities remaining after the transactions.
  • Vesting history: The three options vested in single installments on February 14, 2024; February 14, 2025; and February 14, 2026, respectively, according to the filing's explanatory footnotes.
  • Filing signed by attorney-in-fact: The form was signed by Lily J. Lu as attorney-in-fact for Michael Lane on November 20, 2026.

Lane's Three Incentive Stock Option Exercises at IDEXX Laboratories

According to the Form 4 filed with the SEC on November 20, 2026, Michael Lane, identified in the filing as an Executive Vice President of IDEXX Laboratories Inc /DE, executed three separate incentive stock option exercises on November 18, 2026. The transactions were recorded under transaction code "M" in Table I (non-derivative securities) and Table II (derivative securities), indicating exercises of previously granted stock options.

The filing reports that Lane acquired 483 shares at an exercise price of $206.94, 183 shares at $544.08, and 197 shares at $505.53. Each corresponding option grant is noted as having vested in one installment: the $206.94 grant on February 14, 2024; the $544.08 grant on February 14, 2025; and the $505.53 grant on February 14, 2026. The filing states the price of each derivative security as $0, and all three option positions show zero derivative securities remaining after the reported transactions. Lane's direct beneficial ownership of common stock progressed from 4,076 shares (implied by the sequential reporting) to 4,559, then 4,742, and finally 4,939 shares following the three exercises.

In addition to his direct holdings, the filing discloses that 592 shares are held indirectly by Lane's spouse in an IRA account. The filing states that Lane "disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein." The form was filed by one reporting person, and the signature block reflects execution by Lily J. Lu as attorney-in-fact for Michael Lane.

What Was Disclosed

Michael Lane, an Executive Vice President at IDEXX Laboratories, reported the exercise of three incentive stock option grants totaling 863 shares on November 18, 2026. His direct beneficial ownership of IDEXX common stock stood at 4,939 shares following the transactions, with an additional 592 shares held indirectly by his spouse.